New drug trial aims to protect kids from rare swelling disorder

NCT ID NCT07298447

Recruiting now Disease control Sponsor: Ionis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a drug called donidalorsen in children aged 2 to 12 who have hereditary angioedema (HAE), a rare condition that causes sudden, severe swelling. The main goal is to see if the drug is safe and well-tolerated in young children, and to measure how it works in their bodies. Researchers will also track how well it controls the number and severity of swelling attacks over a one-year treatment period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ionis Investigative Site
RECRUITING

Santa Monica, California, 90404, United States
Ionis Investigative Site
RECRUITING

St Louis, Missouri, 63141, United States
Ionis Investigative Site
RECRUITING

Cincinnati, Ohio, 45236, United States

Conditions

Explore the condition pages connected to this study.

HEREDITARY ANGIOEDEMA (HAE)